Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
None
epsilon toxin
multiple sclerosis
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
24
4
2018
medline:
28
3
2020
entrez:
24
4
2018
Statut:
ppublish
Résumé
It was recently reported that, using Western blotting, some multiple sclerosis (MS) patients in the United States had antibodies against epsilon toxin (Etx) from Clostridium perfringens, suggesting that the toxin may play a role in the disease. We investigated for serum antibodies against Etx in UK patients with clinically definite multiple sclerosis (CDMS) or presenting with clinically isolated syndrome (CIS) or optic neuritis (ON) and in age- and gender-matched controls. We tested sera from CDMS, CIS or ON patients or controls by Western blotting. We also tested CDMS sera for reactivity with linear overlapping peptides spanning the amino acid sequence (Pepscan) of Etx. Using Western blotting, 24% of sera in the combined CDMS, CIS and ON groups ( n = 125) reacted with Etx. In the control group ( n = 125), 10% of the samples reacted. Using Pepscan, 33% of sera tested reacted with at least one peptide, whereas in the control group only 16% of sera reacted. Out of 61 samples, 21 (43%) were positive to one or other testing methodology. Three samples were positive by Western blotting and Pepscan. Our results broadly support the previous findings and the role of Etx in the aetiology of MS warrants further investigation.
Sections du résumé
BACKGROUND
It was recently reported that, using Western blotting, some multiple sclerosis (MS) patients in the United States had antibodies against epsilon toxin (Etx) from Clostridium perfringens, suggesting that the toxin may play a role in the disease.
OBJECTIVE
We investigated for serum antibodies against Etx in UK patients with clinically definite multiple sclerosis (CDMS) or presenting with clinically isolated syndrome (CIS) or optic neuritis (ON) and in age- and gender-matched controls.
METHODS
We tested sera from CDMS, CIS or ON patients or controls by Western blotting. We also tested CDMS sera for reactivity with linear overlapping peptides spanning the amino acid sequence (Pepscan) of Etx.
RESULTS
Using Western blotting, 24% of sera in the combined CDMS, CIS and ON groups ( n = 125) reacted with Etx. In the control group ( n = 125), 10% of the samples reacted. Using Pepscan, 33% of sera tested reacted with at least one peptide, whereas in the control group only 16% of sera reacted. Out of 61 samples, 21 (43%) were positive to one or other testing methodology. Three samples were positive by Western blotting and Pepscan.
CONCLUSION
Our results broadly support the previous findings and the role of Etx in the aetiology of MS warrants further investigation.
Identifiants
pubmed: 29681209
doi: 10.1177/1352458518767327
pmc: PMC6439943
doi:
Substances chimiques
Bacterial Toxins
0
Clostridium perfringens epsilon-toxin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-660Références
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724
pubmed: 28893994
Cell Microbiol. 2015 Mar;17(3):369-88
pubmed: 25287162
Infect Immun. 1992 Mar;60(3):1237-40
pubmed: 1541539
PLoS One. 2012;7(9):e44317
pubmed: 22984492
Vet Microbiol. 2008 Sep 18;131(1-2):14-25
pubmed: 18406080
J Clin Neurosci. 2014 Dec;21(12):2065-71
pubmed: 25027666
PLoS One. 2013 Oct 16;8(10):e76359
pubmed: 24146858
Protein Eng. 1994 Dec;7(12):1501-7
pubmed: 7716162
Aust Vet J. 2003 Apr;81(4):219-21
pubmed: 15080445
Lancet. 1955 Feb 18;268(6860):385
pubmed: 13234393
J Neurol Sci. 2016 Apr 15;363:153-7
pubmed: 27000242
Lancet. 1955 Feb 18;268(6860):384-5
pubmed: 13234392
Nat Struct Mol Biol. 2004 Aug;11(8):797-8
pubmed: 15258571
Lancet Neurol. 2005 May;4(5):281-8
pubmed: 15847841
Nat Commun. 2016 Jun 28;7:12015
pubmed: 27352007
Ann Neurol. 2016 Sep;80(3):443-7
pubmed: 27398819
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
FEBS J. 2011 Dec;278(23):4589-601
pubmed: 21518257
Prog Neurobiol. 2000 Apr;60(6):531-44
pubmed: 10739088
Vaccine. 2014 May 13;32(23):2682-7
pubmed: 24709588
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718
pubmed: 28893978
J Virol. 1990 Jul;64(7):3304-9
pubmed: 1693702
PLoS Pathog. 2015 May 20;11(5):e1004896
pubmed: 25993478
FEBS J. 2011 Dec;278(23):4602-15
pubmed: 21535407
eNeuro. 2017 Aug 10;4(4):
pubmed: 28798954
Toxicon. 2007 Sep 15;50(4):530-40
pubmed: 17572464
Biochim Biophys Acta. 2011 Feb;1812(2):239-45
pubmed: 20600871
PLoS One. 2010 Sep 30;5(9):
pubmed: 20941361